Abstract:Abstract BACKGROUND AND AIMS Calciphylaxis is a rare life-threatening syndrome. Although sodium thiosulfate (STS) showed clinical improvement, some patients presented with serious adverse events and withdrew from treatment. The optimized STS approach included four features: repeated treatment courses, small initial dose, once daily, and escalating low-to-moderate dose. The optimized STS approach, named ‘Zhong Da STS Therapy’ (Zhong Da: the name of a hospital, affiliated with Southeast University, School of Medicine, Nanjing, Jiangsu, China), was generalized with four features: repeated treatment courses, small initial dose, daily medicine, and daily escalating low-to-moderate dose of STS. STS from the initial dose (5 g) was administered intravenously once daily escalating to the highest daily dose as a maintenance dose (no more than 10 g). This study retrospectively evaluated the efficacy and safety of optimized STS therapy for calciphylaxis in China. METHOD The medical records of maintenance hemodialysis or CKD patients who were first diagnosed with calciphylaxis and received STS treatment at Zhong Da Hospital affiliated to Southeast University between October 2017 and October 2019 were retrospectively evaluated. The exclusion criteria of this retrospective study were death at the time of diagnosis (retrospectively confirmed cases) and did not receive the optimized STS approach treatment. The data to evaluate the efficacy included the changes in skin lesions, pain relief, survival rate and laboratory data. Adverse events were summarized as safety parameters. RESULTS The mean age was 51.10 ± 14.85 years old and 71% of patients were male. By October 2019, 87.1% of patients survived, 74.2% markedly improved and 41.9% of patients were followed up for more than 1 year with 100% survival. About 27 (87.10%) patients had typical skin lesions with 66.70% ulceration and skin lesions showed a predominantly peripheral distribution. After the first course, skin lesions improved by 77.8%, and 38.1% of pain sufferers were free from analgesics. The reduction of the Numerical Pain Rating Scale (NPRS) (P < 0.001) is related significantly to the treatment course. Furthermore, during the entire treatment session, more than half of the patients (54.84%) never experienced adverse events, only one withdrew treatment and no one died from complications. And most adverse events appeared in the course of increasing the STS dose and would be relieved when we stopped adding it or decreased to the day-before dose. CONCLUSION Optimized STS therapy is a promising approach for calciphylaxis patients because it is relatively safe and associated with good outcomes.

Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients

Use of the Optimized Sodium Thiosulfate Regimen for the Treatment of Calciphylaxis in Chinese Patients

Multi-modal treatment of calciphylaxis with sodium-thiosulfate, cinacalcet and sevelamer including long-term data

Sodium Thiosulfate: an Emerging Treatment for Calciphylaxis in Dialysis Patients

Success of small-dose fractionated sodium thiosulfate in the treatment of calciphylaxis in a peritoneal dialysis patient

EFFICACY AND SAFETY OF OPTIMIZED SODIUM THIOSULFATE THERAPY FOR CALCIPHYLAXIS IN CHINESE PATIENTS

Systematic Review of Sodium Thiosulfate in Treating Calciphylaxis in Chronic Kidney Disease Patients.

Potential Effect of Sodium Thiosulfate in Calciphylaxis: Remission of Intractable Pain

Successful Treatment of Lung Calciphylaxis With Sodium Thiosulfate in a Patient With Sickle Cell Disease: A Case Report

Sodium-Thiosulfate Induced Life-Threatening Metabolic Acidosis Limiting Treatment of Calciphylaxis

Intravenous treatment of calcinosis cutis with sodium thiosulfate - A case series

Calciphylaxis in dialysis patients, a severe disease poorly responding to therapies: report of 4 cases

Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension

Effects of Intravenous Sodium Thiosulfate on Vascular Calcification in Dialysis Patients with End-Stage Renal Disease: a Systematic Review and Meta-Analysis.

[Calciphylaxis, risk factors, treatment and outcomes. Retrospective study of 39 patients]

Development of calciphylaxis in kidney transplant recipients with a functioning graft

A novel long-term intravenous combined with local treatment with human amnion-derived mesenchymal stem cells for a multidisciplinary rescued uremic calciphylaxis patient and the underlying mechanism

Effectiveness of topical sodium thiosulfate for ectopic calcifications and ossifications. Results of the CATSS-O study

[Calciphylaxis in dialysis patients: To recognize and treat it as soon as possible]

Revisiting therapeutic options for calciphylaxis

Early diagnosis strategy of calciphylaxis in dialysis patients